Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 407-000-3 | CAS number: 127519-17-9 CGL 384; TINUVIN 384
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Subacute NOAEL (rat): 2 mg/kg bw (Annex V; GLP)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- other: Annex V
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- other: Rat (Tif:RAI)
- Route of administration:
- oral: unspecified
- Vehicle:
- other: Distilled water containing 0.5% ‘ CMC' and 0.1 % Tween 80
- Details on oral exposure:
- Method of administration:
Gavage - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 20 animals at 0 mg/kg bw/day
Male: 20 animals at 2 mg/kg bw/day
Male: 20 animals at 50 mg/kg bw/day
Male: 20 animals at 500 mg/kg bw/day
Female: 20 animals at 0 mg/kg bw/day
Female: 20 animals at 2 mg/kg bw/day
Female: 20 animals at 50 mg/kg bw/day
Female: 20 animals at 500 mg/kg bw/day - Details on results:
- Clinical observations:
There were no deaths. Mean body weight was depressed at 500
mg/kg from week 2 for males and in week 4 for females. Food
consumption was similarly depressed. Recovery animals showed
recovery from these effects (Through weeks 5-8).
Laboratory findings:
Mild anaemia, associated with higher reticulocyte counts,
was observed in males at 500 mg/kg. Slightly lower vales for
RBC, HGB, and HCT were observed in males at 50 mg/kg, and in
females at 500 mg/kg.
Slight Hyperglycaemia occurred in both sexes at 500 mg/kg
and 50 mg/kg. Other slight changes included elevated plasma
cholesterol and TGC in females at 500 mg/kg, and decreased
plasma protein in males of the same group. Increased ALP for
both sexes at 500 mg/kg and in males only at 50 mg/kg. ASAT
was increased in males and 2 females at 500 mg/kg.
Effects in organs:
Liver weight was increased in males in all dosed groups,
dose-related, and in females at 500 mg/kg Hepatocyte
hypetrophy was seen in both sexes a! 500 mg/kg and 50
mg/kg. Hepatocyte e necrosis occurred at low incidence in
occasional animals, apparently dose related.
Minimal hypertrophy of the thyroid follicular epithelium
occurred in 2 males in each group a! 500 mg/kg and 50 mg/kg
and in 1 female at 50 mg/kg. - Dose descriptor:
- NOAEL
- Effect level:
- 2 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 2 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Critical effects observed:
- not specified
- Conclusions:
- Classified as: Not classified
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 2 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Information from migrated NONS file, as per inquiry number 06-2120047284-59-0000 ,permission to refer granted by ECHA
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The 28 day repeated oral dose toxicity of Chiguard has been evaluated in 2 studies.
In the repeated dose toxicity supporting study (84/449/EEC B.7/GLP), Chiguard 5599 was administered daily to 20 (Tif:TAlf(SPF)) rats/sex/dose in 0.5 % aqueous carboxymethylcellulose with 0.1 Tween 80 via gavage at dose levels of 0, 2, 50, 500 mg/kg bw/day for 28 days. There were biochemical changes noted in the top dose group in both sexes. There were biochemical and haematological changes noted in the mid dose group in both sexes. There was a dose-dependent increase in the absolute and relative liver weights among the females from the high-dose group and among the males from the medium and high dose groups. Macroscopically, there was an enlargement of the liver among 2 out of 5 males from the medium-dose group and among all of the treated animals from the high-dose group.After the follow-up observation period a slight, dose-dependent increase in liver weight was revealed among the males from the medium and high dose groups. Hypertrophy of the hepatic cells was determined among both sexes in the medium and high dose groups; hepatic cell necrosis also occurred dose-dependently. A NOEL value of 2 mg/kg bw/day was derived from the study.
In the repeated dose toxicity key study (Annex V/GLP), Chiguard 5599 was administered daily to 20 (Tif:RAI)) rats/sex/dose in 0.5 % aqueous carboxymethylcellulose with 0.1 Tween 80 via gavage at dose levels of 0, 2, 50, 500 mg/kg bw/day for 28 days.
There were no deaths. Mean body weight was depressed at 500 mg/kg from week 2 for males and in week 4 for females. Food consumption was similarly depressed. Recovery animals showed recovery from these effects (Through weeks 5-8). Mild anaemia, associated with higher reticulocyte counts, was observed in males at 500 mg/kg. Slightly lower values for RBC, HGB and HCT were observed in males at 50 mg/kg, and in females at 500 mg/kg. Slight hyperglycaemia occurred in both sexes at 500 mg/kg and 50 mg/kg. Other slight changes included elevated plasma cholesterol and TGC in females at 500 mg/kg, and decreased plasma protein in males of the same group. Increased ALP for both sexes at 500 mg/kg and in males only at 50 mg/kg. ASAT was increased in males and females at 500 mg/kg. Liver weight was increased in males in all dosed groups, dose-related, and in females at 500 mg/kg. Hepatocyte hypertrophy was seen in both sexes at 500 mg/kg and 50 mg/kg. Hepatocyte necrosis occurred at low incidence in occasional animals, apparently dose related. Minimal hypertrophy of the thyroid follicular epithelium occurred in 2 males in each group at 500 mg/kg and 50 mg/kg and in 1 female at 50 mg/kg. A NOEL value of 2 mg/kg bw/day and a NOAEL value of 2 mg/kg bw/day was derived from the study. The full study report was not available but the harmonised classification in the ECHA C&L inventory (checked 15-07-15) does not indicate that a STOT-RE classification is warranted.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The key study provides a NOAEL value; the supporting study only provides a NOEL value.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
An oral 28-day study is available.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
An oral 28-day study is available.
Justification for classification or non-classification
Based on the available information in the dossier, the substance Chiguard 5599 (CAS No. 127519-17-9) does not need to be classified as specific target organ toxicity (repeated) when considering the criteria outlined in Annex I of 1272/2008/EC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.